Pay in 4 interest-free payments of $5.22 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Identify gaps in the literature and ongoing research directions Key gaps include a lack of large, controlled clinical trials, unclear optimal dosing and delivery for reproductive targets, limited long-term safety data for systemic use, and few mechanistic human studies linking molecular changes to fertility outcomes
However, there might be a new ally in your weight loss arsenalGLP-1 medications
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
Statements Author contributions AS: Conceptualization, Methodology, Resources, Writing original draft, Writing review & editing
